Literature DB >> 19169384

A Bayesian Framework for Estimating Vaccine Efficacy per Infectious Contact.

Yang Yang1, Peter Gilbert, Ira M Longini, M Elizabeth Halloran.   

Abstract

In vaccine studies for infectious diseases such as human immunodeficiency virus (HIV), the frequency and type of contacts between study participants and infectious sources are among the most informative risk factors, but are often not adequately adjusted for in standard analyses. Such adjustment can improve the assessment of vaccine efficacy as well as the assessment of risk factors. It can be attained by modeling transmission per contact with infectious sources. However, information about contacts that rely on self-reporting by study participants are subject to nontrivial measurement error in many studies. We develop a Bayesian hierarchical model fitted using Markov chain Monte Carlo (MCMC) sampling to estimate the vaccine efficacy controlled for exposure to infection, while adjusting for measurement error in contact-related factors. Our method is used to re-analyze two recent HIV vaccine studies, and the results are compared with the published primary analyses that used standard methods. The proposed method could also be used for other vaccines where contact information is collected, such as human papilloma virus vaccines.

Entities:  

Year:  2008        PMID: 19169384      PMCID: PMC2630256          DOI: 10.1214/08-AOAS193

Source DB:  PubMed          Journal:  Ann Appl Stat        ISSN: 1932-6157            Impact factor:   2.083


  8 in total

Review 1.  Study designs for evaluating different efficacy and effectiveness aspects of vaccines.

Authors:  M E Halloran; C J Struchiner; I M Longini
Journal:  Am J Epidemiol       Date:  1997-11-15       Impact factor: 4.897

2.  Semiparametric methods for multiple exposure mismeasurement and a bivariate outcome in HIV vaccine trials.

Authors:  G T Golm; M E Halloran; I M Longini
Journal:  Biometrics       Date:  1999-03       Impact factor: 2.571

3.  A Bayesian approach to measurement error problems in epidemiology using conditional independence models.

Authors:  S Richardson; W R Gilks
Journal:  Am J Epidemiol       Date:  1993-09-15       Impact factor: 4.897

4.  Subtype-specific transmission probabilities for human immunodeficiency virus type 1 among injecting drug users in Bangkok, Thailand.

Authors:  Michael G Hudgens; Ira M Longini; Suphak Vanichseni; Dale J Hu; Dwip Kitayaporn; Philip A Mock; M Elizabeth Halloran; Glen A Satten; Kachit Choopanya; Timothy D Mastro
Journal:  Am J Epidemiol       Date:  2002-01-15       Impact factor: 4.897

5.  Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.

Authors:  Neil M Flynn; Donald N Forthal; Clayton D Harro; Franklyn N Judson; Kenneth H Mayer; Michael F Para
Journal:  J Infect Dis       Date:  2005-01-27       Impact factor: 5.226

6.  Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand.

Authors:  Punnee Pitisuttithum; Peter Gilbert; Marc Gurwith; William Heyward; Michael Martin; Fritz van Griensven; Dale Hu; Jordan W Tappero; Kachit Choopanya
Journal:  J Infect Dis       Date:  2006-11-03       Impact factor: 5.226

7.  A Markov model for measuring vaccine efficacy for both susceptibility to infection and reduction in infectiousness for prophylactic HIV vaccines.

Authors:  I M Longini; M G Hudgens; M E Halloran; K Sagatelian
Journal:  Stat Med       Date:  1999-01-15       Impact factor: 2.373

8.  Infection with HIV-1 subtypes B and E in injecting drug users screened for enrollment into a prospective cohort in Bangkok, Thailand.

Authors:  D Kitayaporn; S Vanichseni; T D Mastro; S Raktham; T Vaniyapongs; D C Des Jarlais; C Wasi; N L Young; S Sujarita; W L Heyward; J Esparza
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1998-11-01
  8 in total
  5 in total

1.  Apparent declining efficacy in randomized trials: examples of the Thai RV144 HIV vaccine and South African CAPRISA 004 microbicide trials.

Authors:  Justin J O'Hagan; Miguel A Hernán; Rochelle P Walensky; Marc Lipsitch
Journal:  AIDS       Date:  2012-01-14       Impact factor: 4.177

2.  Statistical interpretation of the RV144 HIV vaccine efficacy trial in Thailand: a case study for statistical issues in efficacy trials.

Authors:  Peter B Gilbert; James O Berger; Donald Stablein; Stephen Becker; Max Essex; Scott M Hammer; Jerome H Kim; Victor G Degruttola
Journal:  J Infect Dis       Date:  2011-04-01       Impact factor: 5.226

3.  Contrasting academic and lay press print coverage of the 2013-2016 Ebola Virus Disease outbreak.

Authors:  Mark D Kieh; Elim M Cho; Ian A Myles
Journal:  PLoS One       Date:  2017-06-22       Impact factor: 3.240

4.  Joint modeling of time-varying HIV exposure and infection for estimation of per-act efficacy in HIV prevention trials.

Authors:  Elizabeth R Brown; Clara P Dominguez Islas; Jingyang Zhang
Journal:  Stat Commun Infect Dis       Date:  2020-09-24

5.  Methodological Analysis: Randomized Controlled Trials for Pfizer and Moderna COVID-19 Vaccines.

Authors:  Donna Hallas; Regena Spratling; Jason Fletcher
Journal:  J Pediatr Health Care       Date:  2021-05-31       Impact factor: 1.838

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.